Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study With Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adult Patients With Locally Advanced or Metastatic Solid Tumours and Haematological Malignancies Characterised by Alterations of the NOTCH Signalling Pathway

NCT03422679 is registered in ClinicalTrials.gov with Cellestia Biotech AG as lead sponsor.

NCT NCT03422679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03422679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study With Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adult Patients With Locally Advanced or Metastatic Solid Tumours and Haematological Malignancies Characterised by Alterations of the NOTCH Signalling Pathway
Lead sponsor
Cellestia Biotech AG
Phase
Phase 1/2
Overall status
Terminated
Start date
December 5, 2017
Completion date
November 11, 2022
Enrollment
79 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

adenoid cystic carcinoma, breast cancer, colorectal cancer, glomus tumor, malignant, hepatocellular carcinoma, non-hodgkin lymphoma, osteosarcoma, t-all